| abstract |
A method of treating, preventing or delaying the onset of Alzheimer's disease (AD) in a subject, specifically by inhibiting a novel pathway STAT1-Ch25H in AD development, specifically a pharmaceutically effective amount of STAT1 inhibition. Disclosed is a method by administering to the subject an agent, a CH25H inhibitor or a 25-OHC inhibitor, such as a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, such as simvastatin. [Selection diagram] Fig. 6B |